State-of-the-art therapeutic strategies for targeting cancer stem cells in prostate cancer.
CRISPR
cancer stem cells
chemotherapy
immunotherapy
nanotechnology
photothermal ablation therapy
prostate cancer
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
01
10
2022
accepted:
30
01
2023
entrez:
27
3
2023
pubmed:
28
3
2023
medline:
28
3
2023
Statut:
epublish
Résumé
The development of new therapeutic strategies is on the increase for prostate cancer stem cells, owing to current standardized therapies for prostate cancer, including chemotherapy, androgen deprivation therapy (ADT), radiotherapy, and surgery, often failing because of tumor relapse ability. Ultimately, tumor relapse develops into advanced castration-resistant prostate cancer (CRPC), which becomes an irreversible and systemic disease. Hence, early identification of the intracellular components and molecular networks that promote prostate cancer is crucial for disease management and therapeutic intervention. One of the potential therapeutic methods for aggressive prostate cancer is to target prostate cancer stem cells (PCSCs), which appear to be a primary focal point of cancer metastasis and recurrence and are resistant to standardized therapies. PCSCs have also been documented to play a major role in regulating tumorigenesis, sphere formation, and the metastasis ability of prostate cancer with their stemness features. Therefore, the current review highlights the origin and identification of PCSCs and their role in anti-androgen resistance, as well as stemness-related signaling pathways. In addition, the review focuses on the current advanced therapeutic strategies for targeting PCSCs that are helping to prevent prostate cancer initiation and progression, such as microRNAs (miRNAs), nanotechnology, chemotherapy, immunotherapy, the clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) gene-editing system, and photothermal ablation (PTA) therapy.
Identifiants
pubmed: 36969009
doi: 10.3389/fonc.2023.1059441
pmc: PMC10035756
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1059441Informations de copyright
Copyright © 2023 Ramesh, Selvakumar, Ameer, Lian, Abdullah Alzarooni, Ojha, Mishra, Tiwari, Kaushik, Jung, Chouaib and Lakshmanan.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cancer Res. 2014 Aug 1;74(15):4183-95
pubmed: 24903149
Am J Transl Res. 2021 Feb 15;13(2):617-631
pubmed: 33594313
J Immunother Cancer. 2020 Jul;8(2):
pubmed: 32616555
Am J Pathol. 2011 Jul;179(1):422-35
pubmed: 21703421
BMC Immunol. 2015 Jan 31;16:1
pubmed: 25636521
Sci Rep. 2020 Aug 18;10(1):13958
pubmed: 32811873
J Exp Clin Cancer Res. 2019 May 28;38(1):227
pubmed: 31138311
Antioxid Redox Signal. 2014 Mar 1;20(7):1045-59
pubmed: 23924028
Commun Biol. 2021 Jan 26;4(1):119
pubmed: 33500545
EMBO Rep. 2021 Nov 4;22(11):e53014
pubmed: 34403195
Acta Biomater. 2012 Jul;8(7):2704-11
pubmed: 22484694
J Food Biochem. 2020 Jul;44(7):e13253
pubmed: 32394497
Nat Med. 2011 Feb;17(2):211-5
pubmed: 21240262
Cell Biosci. 2021 May 17;11(1):87
pubmed: 34001269
Stem Cell Res Ther. 2020 Jun 26;11(1):258
pubmed: 32586404
Clin Cancer Res. 2022 Nov 14;28(22):4871-4884
pubmed: 36044531
Cancer Drug Resist. 2022 Jun 01;5(2):459-471
pubmed: 35800367
Life Sci Alliance. 2020 Oct 8;3(12):
pubmed: 33033111
Cancer Lett. 2014 Feb 28;343(2):179-89
pubmed: 24125861
Cancer Res. 2000 Oct 1;60(19):5522-8
pubmed: 11034097
Int J Oncol. 2014 Jul;45(1):362-72
pubmed: 24805183
Biomolecules. 2021 Nov 16;11(11):
pubmed: 34827699
Am J Cancer Res. 2020 Nov 01;10(11):3784-3800
pubmed: 33294267
Oncotarget. 2016 Aug 30;7(35):56628-56642
pubmed: 27447749
Oncol Lett. 2018 Aug;16(2):1821-1826
pubmed: 30008871
N Engl J Med. 2019 Jun 6;380(23):2237-2245
pubmed: 31167052
Exp Mol Med. 2022 Aug;54(8):1290-1305
pubmed: 36042375
J Pathol. 2009 Jan;217(2):299-306
pubmed: 19040209
Exp Hematol Oncol. 2020 Jun 11;9:12
pubmed: 32537260
J Clin Oncol. 2018 Apr 10;36(11):1080-1087
pubmed: 29384722
JAMA Netw Open. 2021 Jan 4;4(1):e2034633
pubmed: 33496795
Mol Cell Biochem. 2014 Aug;393(1-2):265-70
pubmed: 24782036
Signal Transduct Target Ther. 2021 Feb 15;6(1):62
pubmed: 33589595
Asian J Urol. 2016 Oct;3(4):203-210
pubmed: 29264188
J Clin Oncol. 2020 Feb 10;38(5):395-405
pubmed: 31774688
Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12561-6
pubmed: 15314219
Arch Med Res. 2021 Feb;52(2):174-181
pubmed: 33059953
Cells. 2020 Jun 10;9(6):
pubmed: 32531951
Am J Clin Exp Urol. 2014 Jul 12;2(2):161-8
pubmed: 25374919
Nano Converg. 2020 Feb 17;7(1):5
pubmed: 32064551
Cancer Lett. 2021 Oct 10;518:1-9
pubmed: 34118355
Cancer Res. 2018 Jun 15;78(12):3147-3162
pubmed: 29700003
Sci Rep. 2021 May 27;11(1):11210
pubmed: 34045601
Nat Commun. 2017 Jan 23;8:14270
pubmed: 28112170
BMJ Open. 2021 Aug 12;11(8):e046588
pubmed: 34385241
Int J Clin Exp Pathol. 2019 Dec 01;12(12):4361-4379
pubmed: 31933840
BMC Cancer. 2014 Jan 18;14:30
pubmed: 24438073
Prostate. 2020 Jul;80(10):753-763
pubmed: 32421868
J Clin Oncol. 2018 Sep 1;36(25):2639-2646
pubmed: 30028657
Proc Natl Acad Sci U S A. 2017 Jun 27;114(26):E5207-E5215
pubmed: 28611215
J Biomed Sci. 2011 Jan 18;18:6
pubmed: 21241512
Cancer Gene Ther. 2021 Sep;28(9):911-923
pubmed: 33558704
Oncogene. 2019 Feb;38(8):1340-1353
pubmed: 30266990
Cell Res. 2009 Jun;19(6):683-97
pubmed: 19365403
Genes Dis. 2015 Sep;2(3):225-239
pubmed: 26448339
Nat Commun. 2017 Jan 23;8:14284
pubmed: 28112153
Nat Cancer. 2022 Sep;3(9):1071-1087
pubmed: 36065066
World J Mens Health. 2019 Sep;37(3):288-295
pubmed: 30209899
Cell Rep. 2015 Mar 31;10(12):1982-91
pubmed: 25818291
Mol Cancer. 2010 Apr 26;9:89
pubmed: 20420697
Lancet Oncol. 2014 Sep;15(10):1147-56
pubmed: 25104109
Cell Death Dis. 2018 May 9;9(5):523
pubmed: 29743605
Lancet. 2022 Jan 29;399(10323):447-460
pubmed: 34953525
Oncotarget. 2015 Feb 10;6(4):1900-19
pubmed: 25595909
Neoplasia. 2016 Sep;18(9):553-66
pubmed: 27659015
ACS Appl Bio Mater. 2020 Nov 16;3(11):7821-7830
pubmed: 35019522
Bioconjug Chem. 2016 Dec 21;27(12):2911-2922
pubmed: 27809498
Cell Death Dis. 2021 Jul 27;12(8):740
pubmed: 34315855
J Immunother Cancer. 2022 Feb;10(2):
pubmed: 35217575
ACS Pharmacol Transl Sci. 2022 Mar 30;5(4):193-206
pubmed: 35434534
Int J Nanomedicine. 2017 Mar 31;12:2569-2579
pubmed: 28408824
Nat Genet. 2007 Feb;39(2):189-98
pubmed: 17237784
Cancer Res. 2010 Jun 15;70(12):5163-73
pubmed: 20516116
Mol Carcinog. 2019 Jul;58(7):1208-1220
pubmed: 30883933
J Immunother Cancer. 2020 Jun;8(1):
pubmed: 32591433
Int J Nanomedicine. 2008;3(3):351-8
pubmed: 18990944
Endocr Relat Cancer. 2015 Dec;22(6):T209-20
pubmed: 26285606
JAMA Oncol. 2022 Aug 1;8(8):1128-1136
pubmed: 35708696
Proc Natl Acad Sci U S A. 2006 Jan 31;103(5):1480-5
pubmed: 16432235
BMC Cancer. 2013 Feb 05;13:61
pubmed: 23383988
Cancers (Basel). 2015 Nov 18;7(4):2290-308
pubmed: 26593949
Science. 2022 Sep 9;377(6611):1180-1191
pubmed: 35981096
Cell Stem Cell. 2013 Mar 7;12(3):368-82
pubmed: 23333148
Oncol Rep. 2012 Nov;28(5):1831-7
pubmed: 22948942
Clin Cancer Res. 2022 Sep 15;28(18):3979-3989
pubmed: 35816286
Cell Death Dis. 2020 Apr 16;11(4):234
pubmed: 32300100
Stem Cell Rev Rep. 2022 Dec;18(8):2833-2851
pubmed: 35951166
Phytother Res. 2020 Apr;34(4):817-824
pubmed: 31782192
Front Public Health. 2022 Feb 16;10:811044
pubmed: 35252092
Lancet Oncol. 2021 Sep;22(9):1250-1264
pubmed: 34388386
Int J Mol Sci. 2021 Nov 26;22(23):
pubmed: 34884583
Front Cell Dev Biol. 2021 Mar 18;9:656981
pubmed: 33816508
Onco Targets Ther. 2019 Jan 03;12:391-395
pubmed: 30655675
Biomed Pharmacother. 2017 Apr;88:210-217
pubmed: 28107698
Cancer Res. 2005 Dec 1;65(23):10946-51
pubmed: 16322242
Science. 2017 Jan 6;355(6320):84-88
pubmed: 28059768
Proc Natl Acad Sci U S A. 2009 Jan 6;106(1):268-73
pubmed: 19116269
Life Sci. 2019 Aug 15;231:116586
pubmed: 31220528
J Transl Med. 2021 Jan 6;19(1):4
pubmed: 33407591
Stem Cells. 2008 Jun;26(6):1425-35
pubmed: 18403754
PLoS One. 2012;7(3):e32832
pubmed: 22479342
Oncotarget. 2015 Sep 15;6(27):24017-31
pubmed: 26172296
Int J Mol Sci. 2022 Jan 05;23(1):
pubmed: 35008996
PLoS One. 2010 Aug 27;5(8):e12445
pubmed: 20805998
Oncotarget. 2017 Feb 7;8(6):9375-9387
pubmed: 28030843
Cell Rep. 2022 Apr 5;39(1):110595
pubmed: 35385726
Nanomaterials (Basel). 2022 Mar 10;12(6):
pubmed: 35335735
Mol Cancer Res. 2013 Dec;11(12):1597-610
pubmed: 24088787
N Engl J Med. 2018 Apr 12;378(15):1408-1418
pubmed: 29420164
Oncotarget. 2015 Sep 8;6(26):22361-74
pubmed: 26087476
Int J Mol Sci. 2020 Dec 16;21(24):
pubmed: 33339129
Endocrinology. 2006 Mar;147(3):1466-73
pubmed: 16339211
Mol Cancer Ther. 2021 Mar;20(3):577-588
pubmed: 33653946
N Engl J Med. 2003 Jul 24;349(4):366-81
pubmed: 12878745
Eur J Pharm Biopharm. 2015 Jan;89:107-15
pubmed: 25481033
J Clin Invest. 2016 Dec 1;126(12):4585-4602
pubmed: 27820701
PLoS One. 2020 May 15;15(5):e0226057
pubmed: 32413024
N Engl J Med. 2022 Mar 24;386(12):1132-1142
pubmed: 35179323
Ther Adv Urol. 2020 Sep 3;12:1756287220951404
pubmed: 32952615
J Mater Chem B. 2021 Apr 14;9(14):3143-3152
pubmed: 33586760
Am J Pathol. 2015 Sep;185(9):2505-22
pubmed: 26362718
Eur Urol. 2019 Mar;75(3):410-418
pubmed: 30266309
Proc Natl Acad Sci U S A. 2015 Nov 24;112(47):E6544-52
pubmed: 26460041
Biochem Biophys Res Commun. 2016 Jun 10;474(4):722-729
pubmed: 27155154
Carcinogenesis. 2013 Mar;34(3):530-8
pubmed: 23188675
Prostate. 2019 Aug;79(11):1294-1303
pubmed: 31111526
Cancer Res. 2008 Feb 1;68(3):861-9
pubmed: 18245488
Front Pharmacol. 2017 Mar 28;8:153
pubmed: 28400729
Br J Cancer. 2017 Nov 21;117(11):1665-1675
pubmed: 29024936
Theranostics. 2017 Jan 1;7(1):67-80
pubmed: 28042317
Elife. 2019 Dec 19;8:
pubmed: 31855178
Front Oncol. 2020 Oct 08;10:581515
pubmed: 33134178
Nat Commun. 2021 Jul 29;12(1):4601
pubmed: 34326322
Commun Biol. 2020 Jan 15;3(1):26
pubmed: 31942000
Anim Cells Syst (Seoul). 2021 Oct 11;25(5):312-322
pubmed: 34745437
Oncotarget. 2015 Feb 28;6(6):3553-62
pubmed: 25708684
Cancers (Basel). 2019 Mar 27;11(4):
pubmed: 30934773
Clin Cancer Res. 2017 Nov 1;23(21):6744-6756
pubmed: 28751447
Clin Cancer Res. 2005 Apr 1;11(7):2591-6
pubmed: 15814638
Chem Commun (Camb). 2018 Aug 28;54(70):9841-9844
pubmed: 30110025
Biomolecules. 2020 May 30;10(6):
pubmed: 32486234
Nanomedicine. 2017 Feb;13(2):391-401
pubmed: 27520724
Am J Transl Res. 2010 Mar 15;2(2):135-44
pubmed: 20407603
Stem Cells. 2009 Aug;27(8):1712-21
pubmed: 19544444
Cell Cycle. 2009 Jan 1;8(1):149-57
pubmed: 19158486
Clin Cancer Res. 2021 Jul 1;27(13):3602-3609
pubmed: 33795255
Biomed Pharmacother. 2017 Aug;92:108-115
pubmed: 28531799
Acta Pharmacol Sin. 2015 Jan;36(1):3-23
pubmed: 24909511
Cancer Res. 2012 Jul 15;72(14):3618-30
pubmed: 22552290
Br J Cancer. 2008 Feb 26;98(4):756-65
pubmed: 18268494
Essays Biochem. 2022 Sep 16;66(4):291-303
pubmed: 35866337
Cell Stem Cell. 2014 Mar 6;14(3):275-91
pubmed: 24607403
Int J Cancer. 2019 Dec 1;145(11):2974-2985
pubmed: 30968962
Nat Rev Urol. 2016 May;13(5):238
pubmed: 26976245
Oncogene. 2006 Mar 16;25(12):1696-708
pubmed: 16449977
Sci Rep. 2021 Jul 1;11(1):13683
pubmed: 34211036
Nat Commun. 2016 Feb 29;7:10798
pubmed: 26924072
Colloids Surf B Biointerfaces. 2014 Oct 1;122:350-358
pubmed: 25078298
Cold Spring Harb Perspect Med. 2019 Jun 3;9(6):
pubmed: 30291148
J Control Release. 2013 Dec 28;172(3):946-53
pubmed: 24041709
PLoS One. 2013;8(1):e53701
pubmed: 23326489
PLoS One. 2012;7(3):e33729
pubmed: 22442719
Stem Cell Res Ther. 2020 Mar 17;11(1):123
pubmed: 32183880
Front Oncol. 2022 Jul 08;12:935715
pubmed: 35875084
Regen Ther. 2021 Jan 29;17:1-7
pubmed: 33598508
Proc Natl Acad Sci U S A. 2019 Sep 10;116(37):18590-18596
pubmed: 31451630
Cell Commun Signal. 2019 May 23;17(1):50
pubmed: 31122254
JBMR Plus. 2019 May 20;3(7):e10189
pubmed: 31372592
Biomed Pharmacother. 2018 Mar;99:369-374
pubmed: 29358129
Oncogene. 2013 Jan 17;32(3):296-306
pubmed: 22370643
Lab Invest. 2010 Feb;90(2):234-44
pubmed: 20010854
Nanomedicine (Lond). 2018 Apr;13(8):803-807
pubmed: 29485327
Stem Cell Rev Rep. 2014 Apr;10(2):207-29
pubmed: 24323281
Am J Transl Res. 2012;4(4):432-42
pubmed: 23145211
Cell Death Dis. 2013 Aug 29;4:e783
pubmed: 23990023
Cancer Res. 2012 Jul 1;72(13):3393-404
pubmed: 22719071
Int J Biochem Cell Biol. 2017 Apr;85:66-74
pubmed: 28161486
J Biol Chem. 2007 Apr 13;282(15):11221-9
pubmed: 17287208